K.BhardwajR.et al
Clinical trials have shown that GLP-1 receptor agonists, particularly semaglutide and liraglutide, can reduce liver fat content and improve some markers of liver inflammation
Ferroptosis is an iron-dependent regulated cell death due to accumulated lipid peroxidation and involved in physiological processes such as embryonic erythropoiesis and aging
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
While these trials were not specifically designed to assess joint pain, patients with obesity-related joint pain who achieve significant weight loss through GLP-1 therapy often report improved mobility, reduced need for analgesics, and enhanced ability to engage in physical activitycreating a positive cycle of further weight management and joint health
